European Lupus Study for Newly Diagnosed Patients
Part of Immune system & allergy, Skin clinical trials.
This study follows people newly diagnosed with lupus (SLE) to understand how the disease develops over time. It looks at what happens before treatment starts or soon after diagnosis, and aims to improve care for lupus patients across Europe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Systemic Lupus Erythematosus (SLE) or doctors strongly suspect it.
- Your diagnosis should be within the last 6 months, or you have active lupus symptoms (a disease activity score over 6).
- You must be 18 years or older.
- You cannot have other autoimmune diseases like rheumatoid arthritis or scleroderma (except Sjögren's syndrome or antiphospholipid syndrome).
- You cannot be receiving active treatment for cancer (except for non-melanoma skin cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This study is building a national biobank (a storage of blood and health information) to learn more about lupus in people who were recently diagnosed (within the last 2 years). It's for patients whose lupus is not causing serious damage to major organs, so that researchers can study how the disease behaves early on.
This study creates a registry for people with systemic lupus erythematosus (SLE) to track the disease over time. Joining helps researchers learn more about lupus and may improve care for future patients.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.